<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04631601</url>
  </required_header>
  <id_info>
    <org_study_id>20190505</org_study_id>
    <secondary_id>2020-001305-23</secondary_id>
    <nct_id>NCT04631601</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)</brief_title>
  <official_title>A Master Protocol Evaluating the Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a master protocol designed to evaluate the safety and efficacy of investigational&#xD;
      therapies in participants with metastatic castration-resistant prostate cancer (mCRPC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a master protocol designed to evaluate the safety, tolerability, and maximum&#xD;
      tolerated dose (MTD) or recommended phase 2 dose (RP2D) and efficacy of Acapatamab, in&#xD;
      combination with enzalutamide, abiraterone, or the PD1 inhibitor AMG 404, AMG 404&#xD;
      monotherapy, as well as Acapatamab monotherapy, in participants with metastatic&#xD;
      castration-resistant prostate cancer (mCRPC).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 15, 2021</start_date>
  <completion_date type="Anticipated">May 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose exploration only: Number of participants who experience dose limiting toxicities (DLTs)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>The analysis of all endpoints, unless noted otherwise, will be conducted on the Safety Analysis Set defined as all subjects that are enrolled and receive at least 1 dose of Acapatamab. The analysis of dose-limiting toxicity (DLT) will be conducted on the DLT Analysis Set defined as all subjects that are enrolled and receive at least 1 dose of Acapatamab with an evaluable DLT endpoint.&#xD;
The DLT endpoint is evaluable if either:&#xD;
1) the subject experiences a DLT; or 2) the subject does not experience a DLT after receiving all planned doses within the 28-day DLT window in cycle 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants who experience one or more treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>Up to 3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants who experience one or more treatment-related adverse events</measure>
    <time_frame>Up to 3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants who experience a clinically significant change in vital signs</measure>
    <time_frame>Up to 3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants who experience a clinically significant change in clinical laboratory tests</measure>
    <time_frame>Up to 3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate per response evaluation criteria in solid tumors (RECIST) 1.1 with prostate cancer working group 3 (PCWG3) modifications</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who experience circulating tumor cell (CTC) response</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who experience prostate-specific antigen (PSA) response rate</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to subsequent therapy</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum plasma concentration (Cmin)</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve (AUC)</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation ratio based on area under the concentration-time curve (AUC)</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life (t1/2)</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in prostate-specific membrane antigen (PSMA)-positive tumor burden assessed using gallium (GA) 68-labelled PSMA-11 positron emission tomography/computed tomography (PET/CT)</measure>
    <time_frame>Baseline up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in prostate-specific membrane antigen (PSMA)-negative disease burden assessed using 18F-fluorodeoxyglucose (F-FDG) positron emission tomography/computed tomography (PET/CT)</measure>
    <time_frame>Baseline to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to symptomatic skeletal events</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of alkaline phosphatase</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of lactate dehydrogenase (LDH)</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of hemoglobin</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutrophil-to-lymphocyte ratio</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of N-telopeptide in the urine</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>11</number_of_arms>
  <enrollment type="Anticipated">159</enrollment>
  <condition>Metastatic Castration-resistant Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Acapatamab and Enzalutamide: Dose Exploration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The dose-exploration part of the study will estimate the MTD/recommended phase 2 dose (RP2D) of Acapatamab in combination with enzalutamide.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acapatamab and Enzalutamide: Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Following dose exploration, dose expansion will be conducted to confirm the safety and tolerability of the selected dose and to further evaluate the efficacy of Acapatamab in combination with enzalutamide.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acapatamab and Abiraterone: Dose Exploration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The dose exploration part of the study will estimate the MTD/recommended phase 2 dose (RP2D) of Acapatamab in combination with abiraterone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acapatamab and Abiraterone: Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Following dose exploration, dose expansion will be conducted to confirm the safety and tolerability of the selected dose and to further evaluate the efficacy of Acapatamab in combination with abiraterone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acapatamab and AMG 404: Dose Exploration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The dose-exploration part of the study will estimate the MTD/RP2D of Acapatamab in combination with AMG 404.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acapatamab and AMG 404: Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Following dose exploration, dose expansion will be conducted to confirm the safety and tolerability of the selected dose and to further evaluate the efficacy of Acapatamab in combination with AMG 404.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AMG 404 Monotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AMG 404 monotherapy is being conducted to evaluate the preliminary anti-tumor activity of PD-1 inhibition in the mCRPC population.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acapatamab and Enzalutamide: Dose Expansion Asia Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Following dose exploration, dose expansion will be conducted in the Asia cohort at the combination MTD/RP2D determined in dose exploration to confirm the safety, tolerability and PK of Acapatamab in combination with enzalutamide for subjects in Asia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acapatamab and Abiraterone: Dose Expansion Asia Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Following dose exploration, dose expansion will be conducted in the Asia cohort at the combination MTD/RP2D determined in dose exploration to confirm the safety, tolerability and PK of Acapatamab in combination with abiraterone for subjects in Asia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acapatamab and AMG 404: Dose Expansion Asia Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Following dose exploration, dose expansion will be conducted in the Asia cohort at the combination MTD/RP2D determined in dose exploration to confirm the safety, tolerability and PK of Acapatamab in combination with AMG 404 for subjects in Asia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acapatamab Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acapatamab monotherapy is being conducted to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and efficacy of Acapatamab in subjects with mCRPC.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acapatamab</intervention_name>
    <description>Acapatamab will be administered as an intravenous (IV) infusion.</description>
    <arm_group_label>Acapatamab Monotherapy</arm_group_label>
    <arm_group_label>Acapatamab and AMG 404: Dose Expansion</arm_group_label>
    <arm_group_label>Acapatamab and AMG 404: Dose Expansion Asia Cohort</arm_group_label>
    <arm_group_label>Acapatamab and AMG 404: Dose Exploration</arm_group_label>
    <arm_group_label>Acapatamab and Abiraterone: Dose Expansion</arm_group_label>
    <arm_group_label>Acapatamab and Abiraterone: Dose Expansion Asia Cohort</arm_group_label>
    <arm_group_label>Acapatamab and Abiraterone: Dose Exploration</arm_group_label>
    <arm_group_label>Acapatamab and Enzalutamide: Dose Expansion</arm_group_label>
    <arm_group_label>Acapatamab and Enzalutamide: Dose Expansion Asia Cohort</arm_group_label>
    <arm_group_label>Acapatamab and Enzalutamide: Dose Exploration</arm_group_label>
    <other_name>PSMA targeted therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enzalutamide</intervention_name>
    <description>Enzalutamide will be administered orally.</description>
    <arm_group_label>Acapatamab and Enzalutamide: Dose Expansion</arm_group_label>
    <arm_group_label>Acapatamab and Enzalutamide: Dose Expansion Asia Cohort</arm_group_label>
    <arm_group_label>Acapatamab and Enzalutamide: Dose Exploration</arm_group_label>
    <other_name>Androgen receptor inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abiraterone</intervention_name>
    <description>Abiraterone will be administered orally.</description>
    <arm_group_label>Acapatamab and Abiraterone: Dose Expansion</arm_group_label>
    <arm_group_label>Acapatamab and Abiraterone: Dose Expansion Asia Cohort</arm_group_label>
    <arm_group_label>Acapatamab and Abiraterone: Dose Exploration</arm_group_label>
    <other_name>Cytochrome P450 (CYP)17 inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 404</intervention_name>
    <description>AMG 404 will be administered as an intravenous (IV) infusion.</description>
    <arm_group_label>AMG 404 Monotherapy</arm_group_label>
    <arm_group_label>Acapatamab and AMG 404: Dose Expansion</arm_group_label>
    <arm_group_label>Acapatamab and AMG 404: Dose Expansion Asia Cohort</arm_group_label>
    <arm_group_label>Acapatamab and AMG 404: Dose Exploration</arm_group_label>
    <other_name>PD-1 inhibitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        All parts&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥ 18 years of age (or legal adult age within country)&#xD;
&#xD;
          -  Subject has provided informed consent prior to initiation of any study-specific&#xD;
             activities/procedures&#xD;
&#xD;
          -  Subjects with mCRPC with histologically or cytologically confirmed adenocarcinoma of&#xD;
             the prostate&#xD;
&#xD;
          -  Subjects should have undergone bilateral orchiectomy or should be on continuous&#xD;
             androgen deprivation therapy with a gonadotropin releasing hormone agonist or&#xD;
             antagonist (testosterone ≤ 50 ng/dL (or 1.7 nmol/L))&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Central nervous system (CNS) metastases or leptomeningeal disease&#xD;
&#xD;
          -  History or presence of clinically relevant CNS pathology&#xD;
&#xD;
          -  Confirmed history or current autoimmune disease or other diseases requiring permanent&#xD;
             immunosuppressive therapy&#xD;
&#xD;
          -  Myocardial infarction, uncontrolled hypertension, unstable angina, cardiac arrhythmia&#xD;
             requiring medication, and/or symptomatic congestive heart failure (New York Heart&#xD;
             Association &gt; class II) within 12 months&#xD;
&#xD;
          -  Prior treatment with a taxane for mCRPC&#xD;
&#xD;
          -  Major surgery and/or Radiation within 4 weeks&#xD;
&#xD;
          -  History or evidence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)&#xD;
             infection unless agreed upon with medical monitor and meeting the following criteria:&#xD;
&#xD;
               -  Negative test for SARS-CoV-2 RNA by real time polymerase chain reaction (RT-PCR)&#xD;
                  within 72 hours of first dose of Acapatamab (or AMG 404 in Part 3)&#xD;
&#xD;
               -  No acute symptoms of COVID-19 disease within 10 days prior to first dose of&#xD;
                  Acapatamab (or AMG 404 in Part 3) (counted from day of positive test for&#xD;
                  asymptomatic subjects)&#xD;
&#xD;
        Prior/Concurrent Clinical Study Experience&#xD;
&#xD;
          -  Currently receiving treatment in another investigational device or drug study, or less&#xD;
             than 4 weeks since ending treatment on another investigational device or drug&#xD;
             study(ies). Other investigational procedures while participating in this study are&#xD;
             excluded with the exception of investigational scans.&#xD;
&#xD;
        Subprotocol A only:&#xD;
&#xD;
        Inclusion criteria&#xD;
&#xD;
        • Subjects planning to receive enzalutamide for the first time for mCRPC&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  Use of strong CYP2C8 inhibitors or strong CYP3A4 inducers&#xD;
&#xD;
          -  Use of narrow therapeutic index drugs that are substrates of CYP3A4, CYP2C9 or CYP2C19&#xD;
&#xD;
        Subprotocol B only:&#xD;
&#xD;
        Inclusion criteria&#xD;
&#xD;
          -  Subjects planning to receive abiraterone for the first time for mCRPC Exclusion&#xD;
             criteria&#xD;
&#xD;
          -  Baseline moderate and severe hepatic impairment (Child-Pugh Class B and C)&#xD;
&#xD;
          -  Presence of uncontrolled hypertension, hypokalemia, or fluid retention&#xD;
&#xD;
          -  History or presence of adrenocortical insufficiency&#xD;
&#xD;
          -  Use of concomitant medications that are sensitive substrates for CYP2D6 with a narrow&#xD;
             therapeutic index&#xD;
&#xD;
          -  Use of strong CYP3A4 inducers&#xD;
&#xD;
        Subprotocol C only:&#xD;
&#xD;
        Inclusion criteria&#xD;
&#xD;
          -  Subjects who are refractory to a novel antiandrogen therapy. Subjects must be&#xD;
             ineligible for or refuse taxane therapy.&#xD;
&#xD;
          -  Evidence of progressive disease, defined as 1 or more PCWG3 criteria: PSA level &gt;/=1&#xD;
             ng/mL that has increased on at least 2 successive occasions at least 1 week apart,&#xD;
             nodal or visceral progression as defined by RECIST 1.1 with PCGW3 modifications,&#xD;
             and/or appearance of 2 or more new lesions in bone scan Exclusion criteria&#xD;
&#xD;
          -  History or evidence of interstitial lung disease or active, non-infectious pneumonitis&#xD;
&#xD;
          -  Subjects on a prior PD-1 or PD-L1 inhibitor who experienced a grade 3 or higher&#xD;
             immune-related adverse event prior to first day of dose&#xD;
&#xD;
        Subprotocol D only:&#xD;
&#xD;
        Inclusion criteria&#xD;
&#xD;
          -  Subjects may have had novel hormonal therapies (NHT; eg, abiraterone, enzalutamide,&#xD;
             apalutamide, or darolutamide) for prostate cancer, but no more than 1 NHT for&#xD;
             metastatic prostate cancer&#xD;
&#xD;
          -  Ineligible for or refuse taxane therapy&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amgen Call Center</last_name>
    <phone>866-572-6436</phone>
    <email>medinfo@amgen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco Mission Bay Campus</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St Vincents Hospital Sydney</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Kobenhavn O</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Skanes universitetssjukhus</name>
      <address>
        <city>Lund</city>
        <zip>221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Karolinska Universitetssjukhuset Solna</name>
      <address>
        <city>Stockholm</city>
        <zip>171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Akademiska sjukhuset</name>
      <address>
        <city>Uppsala</city>
        <zip>75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital</name>
      <address>
        <city>Sutton</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Denmark</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 13, 2020</study_first_submitted>
  <study_first_submitted_qc>November 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2020</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acapatamab</keyword>
  <keyword>HALF-LIFE EXTENDED (HLE) BITE</keyword>
  <keyword>mCRPC</keyword>
  <keyword>Metastatic Castration-resistant Prostate Cancer</keyword>
  <keyword>68</keyword>
  <keyword>Gallium (68Ga)-prostate-specific membrane</keyword>
  <keyword>antigen (PSMA)-11 positron emission</keyword>
  <keyword>tomography(PET)/computed tomography (CT)</keyword>
  <keyword>and</keyword>
  <keyword>18</keyword>
  <keyword>F-fluorodeoxyglucose (FDG) PET/CT</keyword>
  <keyword>based response evaluation</keyword>
  <keyword>Bispecific T cell Engager</keyword>
  <keyword>BITE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immune Checkpoint Inhibitors</mesh_term>
    <mesh_term>Androgens</mesh_term>
    <mesh_term>Androgen Receptor Antagonists</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.</ipd_time_frame>
    <ipd_access_criteria>Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.</ipd_access_criteria>
    <ipd_url>http://www.amgen.com/datasharing</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

